COMPARISON
Cetrorelix vs Triptorelin
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Cetrorelix is authorised or registered in 10 and Triptorelin in 10 of the 10 registers read. Cetrorelix: No trial states a phase. Triptorelin: highest phase Phase 4 (after approval). 29 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Cetrorelix | Triptorelin | |
|---|---|---|
| Registered trials differs | 140 clinicaltrials.gov · 2026-10-03 | 317 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: cetrorelix acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Trelstar openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-08-31 |
| EU authorised on differs | 1999-04-12 ema · 2026-10-03 | Not checked no record of "authorisedOn" for triptorelin |
| ATC code differs | H01CC02 ema · 2026-10-03 | Not checked no record of "atcCode" for triptorelin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Cetrorelix | placebo | Triptorelin | placebo |
|---|---|---|---|---|
| Nasopharyngitis | 8.9% | 8.7% | - | - |
| Injection site pain | 8.5% | 3.7% | - | - |
| Headache | 7.3% | 7.3% | - | - |
| Upper respiratory infection | 6.9% | 6.0% | - | - |
| Back pain | 6.2% | 6.4% | - | - |
| Diarrhea | 6.0% | 2.8% | - | - |
| Musculoskeletal pain | 6.0% | 2.8% | - | - |
| PSA increased | 5.6% | 2.3% | - | - |
| Hypertension | 4.7% | 5.5% | - | - |
| Arthralgia | 4.2% | 4.6% | - | - |
Trial register Cetrorelix: 2 placebo-controlled trials; Triptorelin: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Cetrorelix side effects · Triptorelin side effects
LEGAL STATUS
Approval in each country read
| Country | Cetrorelix | Triptorelin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
29 registered trials include both
| NCT06396390 | Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes UNKNOWN · updated 2024-07-17 |
|---|---|
| NCT06191809 | Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization UNKNOWN · updated 2024-01-05 |
| NCT04724343 | Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. COMPLETED · updated 2023-10-24 |
| NCT04724486 | Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI COMPLETED · updated 2023-10-24 |
| NCT04727671 | Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. COMPLETED · updated 2023-10-24 |
| NCT04727684 | Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI COMPLETED · updated 2023-10-24 |
| NCT05972902 | Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes UNKNOWN · updated 2023-08-02 |
| NCT04157725 | Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization UNKNOWN · updated 2023-07-20 |
| NCT04616729 | DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation UNKNOWN · updated 2023-05-18 |
| NCT04071574 | Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility COMPLETED · updated 2023-05-09 |
| NCT04537078 | Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders COMPLETED · updated 2022-02-17 |
| NCT05112692 | Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles UNKNOWN · updated 2021-11-09 |
| NCT04854707 | An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data COMPLETED · updated 2021-10-22 |
| NCT03291821 | DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore COMPLETED · updated 2020-12-29 |
| NCT02821819 | Random-start Ovarian Stimulation in Egg-donors (ROSE) TERMINATED · updated 2019-08-19 |
| NCT04008966 | Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles COMPLETED · updated 2019-07-05 |
| NCT02625532 | Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial) UNKNOWN · updated 2018-08-29 |
| NCT03118830 | Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI COMPLETED · updated 2017-11-07 |
| NCT01402336 | GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer COMPLETED · updated 2017-10-10 |
| NCT03139474 | Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality UNKNOWN · updated 2017-05-04 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.